93874Developing treatments to turn back the 'cellular clock'ClosedStudyInnovate UKAgeing is a universal phenomenon and the primary risk factor for most common, chronic human diseases. Our company, SENISCA, is a spin-out from the University of Exeter, initially focussing on developing molecules suitable for treatment of skin ageing, followed by a wider vision to deliver innovative, effective pharmaceutical treatments for age-related diseases. Ageing occurs at the cell and tissue level because of failure of a few basic health maintenance mechanisms. The research leading to SENISCA's patent-protected innovation has identified a novel molecular mechanism of ageing that can be manipulated for cellular rejuvenation. SENISCA's existing data, showing that rejuvenation of senescent cells is possible, gives rise to the possibility of developing treatments for any age-related disease or condition with a senescence component. This project will focus on identifying combinations of naturally occurring or FDA-approved compounds with anti-ageing properties and obtaining primary safety and toxicity data in preparation for out-licensing to the skin ageing market.